 CAMBRIDGE, Mass., Dec. 06, 2020 GLOBE NEWSWIRE -- Constellation Pharmaceuticals, Inc. Nasdaq: CNST today announced that two oral presentations and three posters relating to the Phase 2 MANIFEST and the Phase 3 MANIFEST-2 clinical trials of CPI-0610 in myelofibrosis MF were presented at the American Society of Hematology ASH Annual Meeting and Exposition. The preliminary data in these presentations are based on a data cutoff of September 29, 2020, and reflect an analysis of clinical activity in 63 first-line 1L and 94 second-line 2L or later patients. 